Alnylam Pharmaceuticals
ALNY
ALNY
283 hedge funds and large institutions have $6.68B invested in Alnylam Pharmaceuticals in 2018 Q4 according to their latest regulatory filings, with 30 funds opening new positions, 109 increasing their positions, 99 reducing their positions, and 49 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more ownership
Funds ownership: →
more funds holding in top 10
Funds holding in top 10: →
7% less funds holding
Funds holding: 304 → 283 (-21)
16% less capital invested
Capital invested by funds: $7.94B → $6.68B (-$1.25B)
39% less first-time investments, than exits
New positions opened: 30 | Existing positions closed: 49
Holders
283
Holding in Top 10
9
Calls
$123M
Puts
$53.4M
Top Buyers
| 1 | +$94.2M | |
| 2 | +$75.5M | |
| 3 | +$44.8M | |
| 4 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
+$43.7M |
| 5 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
+$20.7M |
Top Sellers
| 1 | -$77.5M | |
| 2 | -$65.9M | |
| 3 | -$39.4M | |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$38.3M |
| 5 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$18.9M |